久久视频在线视频精品-日韩亚洲变态另类中文-free性欧美69巨大-mm131巨爆乳美女少妇动态图

Recently, Reewarm? PTX Drug Coated Balloon (DCB) Catheter, developed by Endovastec?, has been successfully implanted for the first time in Brazil, showing the product’s continued proliferation in international markets to serve patients worldwide. Dr. Flávio Meireles, Dr. Pedro Vilas Boas, and their team at Paulo Sacramento Hospital in Sao Paulo, Brazil, completed this operation.

Dr. Flávio Meireles and Dr. Pedro Vilas Boas decided to utilize Endovastec?'s Reewarm? PTX DCB Catheter for minimally invasive interventional surgery for a patient with popliteal artery stenosis with collateral circulation and significant symptoms of arterial ischemia. During the operation, the guidewire was passed through the stenotic lesion segment, and balloon expansion was performed to enlarge the narrow area of the popliteal artery. Post-operative angiography showed that the formerly narrowing popliteal artery had clear blood flow and decreased collateral circulation. Furthermore, the patient's lower limb blood circulation had recovered, and the symptoms of arterial ischemia were significantly eased, indicating the operation had been successful.

The Reewarm? PTX DCB Catheter is indicated for Percutaneous Transluminal Angioplasty (PTA) in the peripheral vessels. It is intended for the treatment of femoral-popliteal artery stenosis or occlusion. The balloon carries paclitaxel, which can inhibit the proliferation of smooth muscle cells by acting at lesion sites.

The Reewarm? PTX DCB Catheter is a significant product of Endovastec? in peripheral artery disease treatment. It was launched in China in 2020 and received market approval from the Brazilian Health Regulatory Agency (ANVISA) in 2022. The Reewarm? PTX DCB Catheter has successfully treated over 15,000 patients in China, and the first clinical implantation in Brazil marks a new step in the product's international expansion. In the future, Endovastec? will continue to devote itself to promoting its innovative products to more countries, benefiting patients with peripheral vascular diseases worldwide.